Add to favorites

#Product Trends

BREATHALYSER FROM RBS PROVIDES ULTRA FAST TB SCREENING

Rapid Detection of TB at the Point-of-Care

Rapid Biosensor Systems (RBS), manufacturer of the RBS TB Breathalyser has appointed John Reynolds OBE as Executive Chairman as it moves one step closer to IPO (intial public offering). Based in Cambridge, in the UK, RBS created the TB Breathalyser as a rapid screening device for TB, an infectious device that affects millions worldwide. The company asserts that there is “no other TB test currently on the market that delivers such a rapid response at the point of care.”

The TB Breathalyser analyses patient samples by “performing a displacement assay employing evanescent wave technology.” The system comprises a single use disposable tube for sample collection and a multi-use reader. After being nebulised the patient coughs into the collection tube which contains a glass biosensor coated with a bio-chemical coated that is formulated to react with TB bacilli. The analysis process takes roughly two minutes and the whole screening process from start to finish takes less than ten minutes.

BREATHALYSER FROM RBS PROVIDES ULTRA FAST TB SCREENING

Details

  • Babraham Hall House, Babraham, Cambridge, Cambridgeshire CB22 3AU, UK
  • Rapid Biosensor Systems